|
|
High Bio-Physico-Chemical Comparability of Vmb-015, A Vedolizumab Biosimilar, With the Originator Drug Entyvio®
|
|
|
DOR
|
20.1001.2.9919199705.1399.11.1.84.9
|
نویسنده
|
- - ,- - ,- - ,- - ,- - ,- -
|
منبع
|
كنگره مهندسي شيمي - 1399 - دوره : 11 - یازدهمین کنگره بین المللی مهندسی شیمی - کد همایش: 99191-99705
|
|
|
چکیده
|
Vedolizumab is a humanized igg-1 therapeutic monoclonal antibody (mab) produced recombinantly in chinese hamster ovary (cho) cells, which is marketed under the trade name entyvio® by takeda pharmaceuticals# it was approved by the us fda for treatment of ulcerative colitis and crohn's disease in 2014# vedolizumab selectively targets α4β7 integrin expressed on lymphocyte cell surfaces, blocking its interaction with madcam-1, and thus rendering specific modulation of the inflammatory pathways in the gastrointestinal tract# this article is the first report on development of a vedolizumab biosimilar (vmb-015), carried out by persisgen par co# the nonclinical comparative analytical assessment of vmb-015 included peptide mapping, glycan mapping, charge variants analysis, purity analysis, bioactivity analysis, and analysis of drug osmolality, coloration, clarity and opalescence# the results unanimously demonstrated the high degree of vmb-015 comparability with entyvio®, which confirmed the high quality of manufacturing process development in persisgen par co# biopharmaceutical developer#
|
کلیدواژه
|
Vedolizumab ,Entyvio® ,Biosimilar ,Comparability ,Analytical ,Quality-By-Design
|
آدرس
|
Persisgen Par Co, Iran, Persisgen Par Co, Iran, Persisgen Par Co, Iran, Persisgen Par Co, Iran, Persisgen Par Co, Iran, Persisgen Par Co, Iran
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|